{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:14:31Z","timestamp":1770992071521,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,9,27]],"date-time":"2014-09-27T00:00:00Z","timestamp":1411776000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00345-014-1406-2","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T08:05:27Z","timestamp":1411718727000},"page":"1079-1085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?"],"prefix":"10.1007","volume":"33","author":[{"given":"Axel S.","family":"Merseburger","sequence":"first","affiliation":[]},{"given":"Peter","family":"Hammerer","sequence":"additional","affiliation":[]},{"given":"Francois","family":"Rozet","sequence":"additional","affiliation":[]},{"given":"Thierry","family":"Roumegu\u00e8re","sequence":"additional","affiliation":[]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[]},{"given":"Fernando Calais","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,9,27]]},"reference":[{"issue":"2","key":"1406_CR1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467\u2013479","journal-title":"Eur Urol"},{"key":"1406_CR2","doi-asserted-by":"crossref","unstructured":"Cookson MS, Roth BJ, Dahm P et al (2013) Castration-resistant prostate cancer: AUA guideline","DOI":"10.1016\/j.juro.2013.05.005"},{"key":"1406_CR3","unstructured":"NCCN (2014) NCCN clinical practice guidelines in oncology. Prostate Cancer"},{"issue":"10","key":"1406_CR4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983\u2013992","journal-title":"Lancet Oncol"},{"issue":"2","key":"1406_CR5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148","journal-title":"N Engl J Med"},{"issue":"13","key":"1406_CR6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"5","key":"1406_CR7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433","journal-title":"N Engl J Med"},{"issue":"5","key":"1406_CR8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422","journal-title":"N Engl J Med"},{"issue":"3","key":"1406_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"9747","key":"1406_CR10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS Bono de","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147\u20131154","journal-title":"Lancet"},{"issue":"4","key":"1406_CR11","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.juro.2007.05.129","volume":"178","author":"J Morote","year":"2007","unstructured":"Morote J, Orsola A, Planas J et al (2007) Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178(4):1290\u20131295","journal-title":"J Urol"},{"issue":"2","key":"1406_CR12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2008.02.042","volume":"54","author":"A Alcaraz","year":"2008","unstructured":"Alcaraz A (2008) Management of the hormone sensitivity of prostate cancer: where are we now? Eur Urol 54(2):247\u2013250","journal-title":"Eur Urol"},{"issue":"9","key":"1406_CR13","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.1988.6.9.1456","volume":"6","author":"A Manni","year":"1988","unstructured":"Manni A, Bartholomew M, Caplan R et al (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6(9):1456\u20131466","journal-title":"J Clin Oncol"},{"issue":"10","key":"1406_CR14","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1158\/0008-5472.CAN-06-3332","volume":"67","author":"EA Mostaghel","year":"2007","unstructured":"Mostaghel EA, Page ST, Lin DW et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67(10):5033\u20135041","journal-title":"Cancer Res"},{"issue":"11","key":"1406_CR15","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447\u20134454","journal-title":"Cancer Res"},{"issue":"3","key":"1406_CR16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ctrv.2013.09.011","volume":"40","author":"A Egan","year":"2014","unstructured":"Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O (2014) Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev 40(3):426\u2013433","journal-title":"Cancer Treat Rev"},{"key":"1406_CR17","unstructured":"Philips B, Ball C, Sackett D et al (2009) Oxford Centre for evidence-based medicine levels of evidence"},{"issue":"9","key":"1406_CR18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1464-410X.2005.05821.x","volume":"96","author":"G Attard","year":"2005","unstructured":"Attard G, Belldegrun AS, de Bono JS (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96(9):1241\u20131246","journal-title":"BJU Int"},{"issue":"6","key":"1406_CR19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1200\/JCO.2010.33.7675","volume":"30","author":"E Efstathiou","year":"2012","unstructured":"Efstathiou E, Titus M, Tsavachidou D et al (2012) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30(6):637\u2013643","journal-title":"J Clin Oncol"},{"issue":"6","key":"1406_CR20","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1074\/jbc.M111.261933","volume":"287","author":"HS Soifer","year":"2012","unstructured":"Soifer HS, Souleimanian N, Wu S et al (2012) Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 287(6):3777\u20133787","journal-title":"J Biol Chem"},{"issue":"12","key":"1406_CR21","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M et al (2004) Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12):2317\u20132325","journal-title":"Br J Cancer"},{"issue":"2","key":"1406_CR22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/pcan.2014.8","volume":"17","author":"CJ Ryan","year":"2014","unstructured":"Ryan CJ, Peng W, Kheoh T et al (2014) Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis 17(2):192\u2013198","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"1406_CR23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2011.04.032","volume":"60","author":"G Sonpavde","year":"2011","unstructured":"Sonpavde G, Attard G, Bellmunt J et al (2011) The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol 60(2):270\u2013278","journal-title":"Eur Urol"},{"issue":"2","key":"1406_CR24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00120-012-3054-8","volume":"52","author":"AS Merseburger","year":"2013","unstructured":"Merseburger AS, Kuczyk MA, Wolff JM (2013) Pathophysiology and therapy of castration-resistant prostate cancer. Der Urologe Ausg A 52(2):219\u2013225","journal-title":"Der Urologe Ausg A"},{"issue":"5","key":"1406_CR25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000019634","volume":"33","author":"CJ Tyrrell","year":"1998","unstructured":"Tyrrell CJ, Kaisary AV, Iversen P et al (1998) A randomised comparison of \u2018Casodex\u2019 (bicalutamide) 150\u00a0mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33(5):447\u2013456","journal-title":"Eur Urol"},{"key":"1406_CR26","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/01.ju.0000140159.94703.80","volume":"172","author":"MP Wirth","year":"2004","unstructured":"Wirth MP, See WA, McLeod DG et al (2004) Bicalutamide 150\u00a0mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172:1865\u20131870","journal-title":"J Urol"},{"issue":"4","key":"1406_CR27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","volume":"9","author":"T Visakorpi","year":"1995","unstructured":"Visakorpi T, Hyytinen E, Koivisto P et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9(4):401\u2013406","journal-title":"Nat Genet"},{"issue":"4","key":"1406_CR28","first-page":"803","volume":"59","author":"L Bubendorf","year":"1999","unstructured":"Bubendorf L, Kononen J, Koivisto P et al (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59(4):803\u2013806","journal-title":"Cancer Res"},{"issue":"7","key":"1406_CR29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/pros.21107","volume":"70","author":"H Kawata","year":"2010","unstructured":"Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y (2010) Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 70(7):745\u2013754","journal-title":"Prostate"},{"issue":"17","key":"1406_CR30","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1073\/pnas.0500381102","volume":"102","author":"CE Bohl","year":"2005","unstructured":"Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102(17):6201\u20136206","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1406_CR31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mce.2012.10.002","volume":"365","author":"S Belikov","year":"2013","unstructured":"Belikov S, Oberg C, Jaaskelainen T, Rahkama V, Palvimo JJ, Wrange O (2013) FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide). Mol Cell Endocrinol 365(1):95\u2013107","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"1406_CR32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cas.12206","volume":"104","author":"GT Lee","year":"2013","unstructured":"Lee GT, Jung YS, Ha YS, Kim JH, Kim WJ, Kim IY (2013) Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Sci 104(8):1027\u20131032","journal-title":"Cancer Sci"},{"key":"1406_CR33","author":"E Efstathiou","year":"2014","unstructured":"Efstathiou E, Titus M, Wen S et al (2014) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. doi: 10.1016\/j.eururo.2014.05.005","journal-title":"Eur Urol"},{"issue":"5928","key":"1406_CR34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787\u2013790","journal-title":"Science"},{"issue":"15","key":"1406_CR35","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/jco.2013.31.15_suppl.5001","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith MR, Borre M, Rathenborg P et al (2013) Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). J Clin Oncol 31(15):5001","journal-title":"J Clin Oncol"},{"issue":"6","key":"1406_CR36","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.urology.2007.09.066","volume":"71","author":"GW Bong","year":"2008","unstructured":"Bong GW, Clarke HS, Hancock WC, Keane TE (2008) Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 71(6):1177\u20131180","journal-title":"Urology"},{"key":"1406_CR37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/sj.bjc.6604051","volume":"98","author":"J Shamash","year":"2008","unstructured":"Shamash J, Davies A, Ansell W et al (2008) A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 98:22\u201324","journal-title":"Br J Cancer"},{"issue":"11","key":"1406_CR38","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1200\/JCO.1993.11.11.2167","volume":"11","author":"CD Taylor","year":"1993","unstructured":"Taylor CD, Elson P, Trump DL (1993) Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11(11):2167\u20132172","journal-title":"J Clin Oncol"},{"issue":"9","key":"1406_CR39","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.1994.12.9.1868","volume":"12","author":"M Hussain","year":"1994","unstructured":"Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M (1994) Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12(9):1868\u20131875","journal-title":"J Clin Oncol"},{"issue":"2","key":"1406_CR40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/COC.0b013e3181d2ed7d","volume":"34","author":"JL Lee","year":"2011","unstructured":"Lee JL, Eun Kim J, Ahn JH et al (2011) Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. Am J Clin Oncol 34(2):140\u2013144","journal-title":"Am J Clin Oncol"},{"issue":"15","key":"1406_CR41","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502\u20131512","journal-title":"N Engl J Med"},{"issue":"7","key":"1406_CR42","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148\u20131159","journal-title":"J Clin Oncol"},{"issue":"2","key":"1406_CR43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149\u2013158","journal-title":"Lancet Oncol"},{"issue":"30","key":"1406_CR44","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith MR, Saad F, Oudard S et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31(30):3800\u20133806","journal-title":"J Clin Oncol"},{"key":"1406_CR45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","volume":"13","author":"MR Sydes","year":"2012","unstructured":"Sydes MR, Parmar MK, Mason MD et al (2012) Flexible trial design in practice\u2014stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 13:168","journal-title":"Trials"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-014-1406-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-014-1406-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-014-1406-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T22:55:22Z","timestamp":1650236122000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-014-1406-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,27]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1007\/s00345-014-1406-2","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,27]]}}}